Ember Therapeutics

Ember Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of regenerative medicines through the application of bone morphogenetic protein-7 (BMP-7). The company aims to address various health conditions, including osteoarthritis, insulin resistance, and organ fibrosis associated with chronic kidney disease and Alport syndrome, as well as metabolic diseases such as obesity and type 2 diabetes. Ember's lead product candidates include MT-006, which has completed a Phase 2a clinical trial for osteoarthritis, and several preclinical candidates targeting chronic kidney disease and metabolic disorders. The company holds approximately 450 patents related to BMP-7 and its derivatives, focusing on innovative formulations and delivery technologies. Ember Therapeutics was founded in 2010 and has positioned itself at the forefront of addressing the rising epidemic of metabolic diseases through its proprietary research in brown fat biology and insulin sensitization.

Michael Solomon

COO

Kevin Starr

Interim CEO

2 past transactions

DermaSilk Brands

Acquisition in 2016
DermaSilk Brands, Inc. is a manufacturer of anti-aging cosmetic products and nutritional supplements, focusing on solutions for aging skin, eyes, face, neck, and wrinkles. The company offers a diverse range of products, including facial masks, collagen lifts, wrinkle erase pens, beauty peels, and various lifting solutions for different facial areas. Their offerings also include night repairing treatments and skin perfecting solutions, which are designed to enhance skin appearance and texture. DermaSilk Brands distributes its products through retail stores and is headquartered in New Brunswick, New Jersey. As of September 2016, it operates as a subsidiary of Ember Therapeutics, Inc.

Migralex

Acquisition in 2016
Migralex, Inc. is a New York-based company that develops and sells over-the-counter medications specifically designed for headache relief. Founded in 1992 and currently operating as a subsidiary of Ember Therapeutics, Migralex offers a unique headache remedy that does not contain caffeine, distinguishing it from many other headache medications that often include this stimulant. The company's product addresses various types of headaches, including tension, sinus, stress, menstrual, and hangover headaches. Migralex distributes its products through retail outlets and online platforms, making it accessible to a wide range of consumers seeking effective headache relief without the potential complications associated with caffeine consumption.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.